ArticleAmerican journal of translational research2026
Dabigatran outperforms warfarin in elderly patients with atrial fibrillation and stable coronary artery disease: reduced risks of bleeding and cardiovascular events.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study compares the safety of dabigatran versus warfarin in elderly patients with atrial fibrillation and stable coronary artery disease, who face higher stroke and bleeding risks due to anticoagulation needs.
methodsThis retrospective cohort study included patients aged ≥ 65 years who initiated anticoagulation therapy between June 1, 2021 and June 2, 2024. Patients were divided into dabigatran and warfarin groups. Coagulation functions were assessed at baseline and one month post-treatment. Bleeding events and major adverse cardiovascular events were recorded over the 12-month follow-up. Treatment adherence was evaluated at one and three month intervals.
resultsA cohort of 218 patients was analyzed, with 102 in the dabigatran group and 116 in the warfarin group, showing comparable baseline characteristics. One month post-treatment, activated partial thromboplastin time was higher in the dabigatran group (42.11 vs. 40.89, P=0.007), while D-dimer levels were lower (0.55 vs. 0.58, P=0.003). The annual incidence rates of major bleeding (3.92% vs. 12.93%, P=0.019) and intracranial hemorrhage (0.98% vs. 7.76%, P=0.039) were significantly lower in the dabigatran group. Total bleeding events were also lower in the dabigatran group (16.67% vs. 31.90%, P=0.009). Dabigatran group showed reduced rates of ischemic stroke (0.98% vs. 7.76%, P=0.039) and acute myocardial infarction (1.96% vs. 8.62%, P=0.031). Good compliance at 3 months was higher in the dabigatran group (83.3% vs. 69.8%, P=0.020).
conclusionsIn senior individuals with atrial fibrillation and stable coronary artery disease, dabigatran is associated with better control of thrombotic activity, lower bleeding risk, and a higher medication compliance compared to warfarin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.